Calquence CLL rr Japan PMS_Japan Post-Marketing Surveillance (PMS) Study - All Patient Investigation

Study identifier:D8224C00001

ClinicalTrials.gov identifier:NCT04872621

EudraCT identifier:N/A

CTIS identifier:N/A

Recruitment Complete

Official Title

Calquence 100 mg capsules General Drug Use-Results Study; All Patient Investigation in patients with relapsed or refractory chronic lymphocytic leukemia (including small lymphocytic lymphoma)

Medical condition

relapsed or refractory Chronic Lymphocytic Leukemia (including Small Lymphocytic Lymphoma)

Phase

N/A

Healthy volunteers

No

Study drug

-

Sex

All

Actual Enrollment

104

Study type

Observational

Age

n/a - n/a

Date

Study Start Date: 30 Jun 2021
Estimated Primary Completion Date: 30 Sept 2024
Estimated Study Completion Date: 30 Sept 2024

Study design

Allocation: N/A
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

Verified 01 Nov 2023 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria